Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer
Clinicaltrials.gov identifier:
NCT05328908
treatment study for people with metastatic colorectal cancer
Study Contact Information:
For additional information, please contact:
BMS Study Connect Contact Center by phone at (855) 907-3286
or by email at [email protected]. The first line of the email must contain NCT05328908 and the Site #
Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer
About the Study
This study is no longer recruiting people.
This study is being done to look at how well a combination of three drugs works for the treatment of colorectal cancer in patients who have had their cancer come back or get worse after treatment. The study is open to people who have had at least one, but no more than four courses of treatment in the setting.
What the Study Entails
Participants will be randomly selected to participate in either group and they will know which treatment they are receiving.
This study has two groups:
- Group 1: Patients will receive Opdualag, which is a combination of two drugs, nivolumab and relatlimab, injected into the vein.
- Group 2: Patients will receive either Stivarga (regorafenib) orally or Lonsurf orally.
Study Sites
Arkansas
- Springdale
Highlands Oncology Group - Springdale (Site 0044)
Contact: J. Thaddeus Beck (479) 872-8130
California
- Los Angeles
USC Norris Comprehensive Cancer Center (Site 0012)
Contact: Heinz-Josef Lenz (323) 865-3967
Connecticut
- Norwich
Eastern Connecticut HEmatology and Oncology (Site 0117)
Contact: Dennis Slater (860) 886-8362
Florida
- Miami
Baptist Hospital of Miami (Site 0025)
Contact: Antonio Ucar (305) 607-8732
Georgia
- Atlanta
Northside Hospital (Site 0031)
Contact: Ioana Bonta (773) 814-8646
Idaho
- Boise
St. Luke’s Cancer Institute - Boise (Site 0071)
Contact: Dan Zuckerman
Indiana
- Fort Wayne
Fort Wayne Medical Oncology and Hematology (Site 0081)
Contact: Sunil Babu (260) 436-0800
Massachusetts
- Boston
Massachusetts General Hospital (Site 0140)
Contact: Aparna Parikh (847) 971-3738
Michigan
- Ann Arbor
University of Michigan - Rogel Cancer Center (Site 0042)
Contact: John Krauss (734) 645-3109
New Jersey
- East Brunswick
Astera Cancer Care (Site 0043)
Contact: Phillip Reid (617) 632-2000
North Carolina
- Durham
Duke University Medical Center (Site 0009)
Contact: Michael Morse (919) 681-3480
Ohio
- Cincinnati
Good Samaritan Hospital (Site 0082)
Contact: David Draper (513) 442-5561 - Columbus
The James Cancer Hospital and Solove Research Institute at the Ohio State
University Comprehensive Center (Site 0079)
Contact: Anne Noonan (614) 293-9496 - Columbus
The James Cancer Hospital (Site 0095)
Contact: Pannaga Malalur (614) 293-3717
Pennsylvania
- Philadelphia
Thomas Jefferson University - Clinical Trials Office-Medical Oncology (Site 0130)
Contact: Atrayee Basu-Mallick (347) 267-7604 - Philadelphia
Fox Chase Cancer Center (Site 0147)
Contact: Namrata Vijayvergia (215) 214-1676
South Carolina
- Charleston
Roper Hospital (Site 0008)
Contact: David Ellison (843) 577-6957
South Dakota
- Sioux Falls
Sanford Research (Site 0096)
Contact: Jonathan Bleeker (605) 328-8000
Tennessee
- Nashville
Tennessee Oncology (Site 0127)
Contact: Meredith Pelster (615) 329-7274
Texas
- Fort Worth
The Center For Cancer and Blood Disorders (Site 0097)
Contact: Henry Xiong (817) 759-7000
Virginia
- Richmond
Virginia Commonwealth University Massey Cancer Center (Site 0132)
Contact: Khalid Matin (608) 265-1700
Wisconsin
- Madison
University of Wisconsin-Madison - Wisconsin Institutes for Medical Research (Site 0005)
Contact: Dustin Deming (608) 265-1700
This study is no longer recruiting people.
This study is no longer recruiting people.